Sunitinib Malate APIs from Loncom Pharma are a key component in multi-targeted receptor tyrosine kinase inhibitors, used for renal cell carcinoma and gastrointestinal stromal tumors, demonstrating Loncom Pharma's commitment to comprehensive cancer care.
Shandong Loncom Pharmaceutical Co., Ltd is founded in 2012, located in Qihe Economic Development Zone, Shandong Province, with a registered capital of 60 million yuan.
